Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 12
Submit an article Journal homepage
132
Views
71
CrossRef citations to date
0
Altmetric
Original Article

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

T. D. Filippatos Department of Internal Medicine, Medical School, University of Ioannina, Greece
,
D. N. Kiortsis Laboratory of Physiology, Medical School, University of Ioannina, Greece
,
E. N. Liberopoulos Department of Internal Medicine, Medical School, University of Ioannina, Greece; Department of Clinical Biochemistry Royal Free and University College Medical School, London, UK
,
M. Georgoula Department of Internal Medicine, Medical School, University of Ioannina, Greece
,
D. P. Mikhailidis Department of Clinical Biochemistry Royal Free and University College Medical School, London, UK
&
M. S. Elisaf Department of Internal Medicine, Medical School, University of Ioannina, GreeceCorrespondence[email protected]
Pages 1997-2006 | Accepted 19 Oct 2005, Published online: 04 Nov 2005

Citations (71)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (18)

T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Theodosios D Filippatos & Moses S Elisaf. (2015) Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 14:9, pages 1481-1493.
Read now
Khaled Nashar & Brent M Egan. (2014) Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes, Metabolic Syndrome and Obesity 7, pages 421-435.
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, pages 345-349.
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Aris P Agouridis, Theodosios D Filippatos, Vasilios Tsimihodimos & Moses S Elisaf. (2011) Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy 9:3, pages 355-366.
Read now
Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf & Haralampos J Milionis. (2010) Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular Health and Risk Management 6, pages 525-539.
Read now
Giuseppe Derosa, Pamela Maffioli, Sibilla AT Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Angela D'Angelo, Elena Fogari, Ilaria Palumbo, Sabrina Randazzo & Arrigo FG Cicero. (2010) Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opinion on Pharmacotherapy 11:12, pages 1971-1982.
Read now
Vasilios G. Athyros, Emmanuel S. Ganotakis, Konstantinos Tziomalos, Athanasios A. Papageorgiou, Panagiotis Anagnostis, Theodora Griva, Konstantinos Kargiotis, Eydoxia K. Mitsiou, Asterios Karagiannis & Dimitri P. Mikhailidis. (2010) Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Current Medical Research and Opinion 26:3, pages 713-719.
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
M Florentin, EN Liberopoulos, TD Filippatos, C Kostara, A Tselepis, DP Mikhailidis & M Elisaf. (2008) Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opinion on Pharmacotherapy 9:16, pages 2741-2750.
Read now
Theodosios Filippatos & Haralampos J Milionis. (2008) Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opinion on Investigational Drugs 17:10, pages 1599-1614.
Read now
E Nakou, TD Filippatos, EN Liberopoulos, AD Tselepis, DN Kiortsis, DP Mikhailidis & MS Elisaf. (2008) Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opinion on Pharmacotherapy 9:10, pages 1629-1639.
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Dimitri P Mikhailidis & Martin Press. (2007) The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 8:17, pages 3009-3020.
Read now
Cristina Bianchi, Giuseppe Penno, Fabiola Romero, Stefano Del Prato & Roberto Miccoli. (2007) Treating the metabolic syndrome. Expert Review of Cardiovascular Therapy 5:3, pages 491-506.
Read now
Maria C. Diakou, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Epaminondas V. Tsianos, Andrew K. Burroughs & Moses S. Elisaf. (2007) Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. Scandinavian Journal of Gastroenterology 42:2, pages 139-147.
Read now

Articles from other publishers (53)

T. D. Filippatos, K. Alexakis, V. Mavrikaki & D. P. Mikhailidis. (2021) Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis. Digestive Diseases and Sciences 67:1, pages 26-41.
Crossref
Soheila Noori, Atieh Mirzababaei, Mohammad Reza Amini, Cain C. T. Clark & Khadijeh Mirzaei. (2021) Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials. International Journal of Clinical Practice 75:11.
Crossref
Jie Zhang, Xiaopeng Ji, Zehua Dong, Jie Lu, Yuhang Zhao, Runze Li, Changgui Li & Ying Chen. (2021) Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. Endocrine Journal 68:7, pages 829-837.
Crossref
Mercedes Dávalos-Salas, John M. Mariadason, Matthew J. Watt & Magdalene K. Montgomery. (2020) Molecular regulators of lipid metabolism in the intestine – Underestimated therapeutic targets for obesity?. Biochemical Pharmacology 178, pages 114091.
Crossref
Cheng, Tan, Low, Marvalim, Lee & Tan. (2019) Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. International Journal of Molecular Sciences 20:20, pages 5055.
Crossref
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck & Dimitrios N. Kiortsis. (2019) Semaglutide as a promising antiobesity drug. Obesity Reviews 20:6, pages 805-815.
Crossref
Swaramya Chandrasekaran & Haritha Sagili. (2018) Metabolic syndrome in women with polycystic ovary syndrome. The Obstetrician & Gynaecologist 20:4, pages 245-252.
Crossref
Theodosios D. Filippatos, Anastazia Kei, Christos V. Rizos & Moses S. Elisaf. (2017) Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Journal of Cardiovascular Pharmacology and Therapeutics 23:1, pages 3-12.
Crossref
Ekaterina Vladimirovna Ershova, Ekaterina Anatol'evna Troshina & Kseniya Andreevna Komshilova. (2016) Xenical in clinical practice. Obesity and metabolism 12:4, pages 18-22.
Crossref
Theodosios D. Filippatos, Evangelos N. Liberopoulos & Moses S. Elisaf. (2014) Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 6:1, pages 29-41.
Crossref
Niki Katsiki, Dimitri P. Mikhailidis & Devaki R. Nair. (2014) The effects of antiepileptic drugs on vascular risk factors: A narrative review. Seizure 23:9, pages 677-684.
Crossref
Sanaa R. Galaly, Walaa G. Hozayen, Kamal A. Amin & Shimaa M. Ramadan. (2014) Effects of Orlistat and herbal mixture extract on brain, testes functions and oxidative stress biomarkers in a rat model of high fat diet. Beni-Suef University Journal of Basic and Applied Sciences 3:2, pages 93-105.
Crossref
Niki Katsiki, Asterios Karagiannis, Vasilios G. Athyros & Dimitri P. Mikhailidis. (2013) Hyperuricaemia. Journal of Cardiovascular Medicine 14:6, pages 397-402.
Crossref
Theodosios D. Filippatos, Evangelos C. Rizos, Vasilios Tsimihodimos, Irene F. Gazi, Alexandros D. Tselepis & Moses S. Elisaf. (2013) Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes. Lipids 48:6, pages 547-555.
Crossref
Michael S. Kostapanos, Matilda Florentin & Moses S. Elisaf. (2013) Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation 43:5, pages 522-531.
Crossref
Michael S Kostapanos. (2013) Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 5:9, pages 470.
Crossref
Michael S. Kostapanos, Vasilios G. Athyros, Dimitri P. Mikhailidis & Moses S. Elisaf. (2013) Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. Journal of Clinical Lipidology 7:1, pages 88.
Crossref
Ioanna Paspala, Niki Katsiki, Dorothea Kapoukranidou, Dimitri P Mikhailidis & Anna Tsiligiroglou-Fachantidou. (2012) The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity. The Open Cardiovascular Medicine Journal 6:1, pages 147-155.
Crossref
Corine den Engelsen, Kees J Gorter, Philippe L Salomé, Maureen van den Donk & Guy E Rutten. (2012) Remission of screen-detected metabolic syndrome and its determinants: an observational study. BMC Public Health 12:1.
Crossref
A. P. Agouridis, M. S. Kostapanos, V. Tsimihodimos, C. Kostara, D. P. Mikhailidis, E. T. Bairaktari, A. D. Tselepis & M. S. Elisaf. (2012) Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. International Journal of Clinical Practice 66:9, pages 843-853.
Crossref
Jennifer Santee, Cameron Lindsey & Heather Pace. (2012) Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction. Journal of Pharmacy Practice 25:4, pages 447-456.
Crossref
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Kate McKeage & Gillian M. Keating. (2011) Fenofibrate. Drugs 71:14, pages 1917-1946.
Crossref
Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor & Peter Zahradka. 2011. Metabolic Syndrome. Metabolic Syndrome 73 131 .
Yi-Jing Sheen & Wayne Huey-Herng Sheu. (2011) Metabolic Syndrome and Renal Injury. Cardiology Research and Practice 2011, pages 1-13.
Crossref
Christos S. Derdemezis, Theodosios D. Filippatos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2010) Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 120-134.
Crossref
Matilda Florentin, Evangelos N. Liberopoulos, Costas C. Tellis, Christos S. Derdemezis, Moses Elisaf & Alexandros Tselepis. (2009) Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study. Angiology 61:4, pages 365-371.
Crossref
E. S. Nakou, T. D. Filippatos, A. P. Agouridis, C. Kostara, E. T. Bairaktari & M. S. Elisaf. (2010) The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients. Lipids 45:5, pages 445-450.
Crossref
P. EvangelouM.D.M.D., T. TzotzasM.D.M.D., G. ChristouM.D.M.D., M.S. ElisafM.D., Ph.DM.D., Ph.DD.N. KiortsisM.D., Ph.DM.D., Ph.D. (2010) Does the Presence of Metabolic Syndome Influence Weight Loss in Obese and Overweight Women?. Metabolic Syndrome and Related Disorders 8:2, pages 173-178.
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in patients with non-alcoholic fatty liver disease. World Journal of Hepatology 2:4, pages 139.
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in obese diabetic patients. World Journal of Diabetes 1:1, pages 8.
Crossref
Azadeh Zabetian, Farzad Hadaegh, Parvin Sarbakhsh & Fereidoun Azizi. (2009) Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. BMC Public Health 9:1.
Crossref
Matilda Florentin, Michael S. Kostapanos, Eleni S. Nakou, Moses ElisafEvangelos N. Liberopoulos. (2009) Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:4, pages 274-282.
Crossref
David J. Heal, Jane Gosden & Sharon L. Smith. (2009) Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology 68:6, pages 861-874.
Crossref
Varun Agrawal, Aashish Shah, Casey Rice, Barry A. Franklin & Peter A. McCullough. (2009) Impact of treating the metabolic syndrome on chronic kidney disease. Nature Reviews Nephrology 5:9, pages 520-528.
Crossref
Konstantinos Tziomalos, Emmanuel S Ganotakis, Irene F Gazi, Devaki R Nair & Dimitri P Mikhailidis. (2009) Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. The Open Cardiovascular Medicine Journal 3:1, pages 57-68.
Crossref
N V Mazurina & N V Masurina. (2009) The influence of orlistat (Xenical) therapy on the parameters of lipid metabolism in patients with obesity. Obesity and metabolism 6:2, pages 7-11.
Crossref
TD Filippatos, CS Derdemezis & MS Elisaf. (2009) Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clinical Lipidology 4:3, pages 331-341.
Crossref
Theodosios D. Filippatos, Vasilis Tsimihodimos, Michael Kostapanos, Christina Kostara, Eleni T. Bairaktari, Dimitrios N. Kiortsis & Moses S. Elisaf. (2008) Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. Journal of Clinical Lipidology 2:4, pages 279-284.
Crossref
T. D. Filippatos, E. N. Liberopoulos, M. Kostapanos, I. F. Gazi, E. C. Papavasiliou, D. N. Kiortsis, A. D. Tselepis & M. S. Elisaf. (2008) The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes, Obesity and Metabolism 10:6, pages 476-483.
Crossref
J A Batsis, R E Nieto-Martinez & F Lopez-Jimenez. (2007) Metabolic Syndrome: From Global Epidemiology to Individualized Medicine. Clinical Pharmacology & Therapeutics 82:5, pages 509-524.
Crossref
T.D. Filippatos, I.F. Gazi, E.N. Liberopoulos, V.G. Athyros, M.S. Elisaf, A.D. Tselepis & D.N. Kiortsis. (2007) The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193:2, pages 428-437.
Crossref
Zafar H Israili, Badiâa Lyoussi, Rafael Hernández-Hernández & Manuel Velasco. (2007) Metabolic Syndrome: Treatment of Hypertensive Patients. American Journal of Therapeutics 14:4, pages 386-402.
Crossref
Vasilios G. Athyros, Emmanuel S. Ganotakis, Moses S. Elisaf, Evangelos N. Liberopoulos, Ioannis A. Goudevenos & Asterios Karagiannis. (2007) Prevalence of vascular disease in metabolic syndrome using three proposed definitions. International Journal of Cardiology 117:2, pages 204-210.
Crossref
T. D. Filippatosm, C. S. Derdemezis, D. N. Kiortsis, A. D. Tselepis & M. S. Elisaf. (2014) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. Journal of Endocrinological Investigation 30:4, pages 323-326.
Crossref
Themistoklis Tzotzas, Martha Samara, Theodoros Constantinidis, Konstantinos Tziomalos & Gerasimos Krassas. (2016) Short-term Administration of Orlistat Reduced Daytime Triglyceridemia in Obese Women With the Metabolic Syndrome. Angiology 58:1, pages 26-33.
Crossref
Gillian M Keating & Katherine F Croom. (2007) Fenofibrate. Drugs 67:1, pages 121-153.
Crossref
Stuart M GrieveJean-Claude AnsquerAnthony C Keech. (2006) Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology 2:6, pages 635-646.
Crossref
Sofia G. Tsouli, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Vasilios G. Athyros & Moses S. Elisaf. (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism 55:10, pages 1293-1301.
Crossref
Ambika Babu & Leon Fogelfeld. (2006) Metabolic Syndrome and Prediabetes. Disease-a-Month 52:2-3, pages 55-144.
Crossref
Sheridan Henness & Caroline M Perry. (2006) Orlistat. Drugs 66:12, pages 1625-1656.
Crossref
Jan O. Nehlin. 2006. Prevention and Treatment of Age-related Diseases. Prevention and Treatment of Age-related Diseases 133 157 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.